These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 2568553)

  • 1. Adverse effect of tamoxifen with LHRH agonist on oestrogen-receptor-negative mammary carcinoma.
    Szende B; Schally AV; Srkalovic G; Comaru-Schally AM; Wittliff JL
    Lancet; 1989 Jul; 2(8656):222-3. PubMed ID: 2568553
    [No Abstract]   [Full Text] [Related]  

  • 2. Adjuvant tamoxifen therapy for early breast cancer: an experimental study with reference to oestrogen and progesterone receptors.
    Wilson AJ; Tehrani F; Baum M
    Br J Surg; 1982 Mar; 69(3):121-5. PubMed ID: 7066649
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Endocrine and antitumor effects of combined treatment with an antiprogestin and antiestrogen or luteinizing hormone-releasing hormone agonist in female rats bearing mammary tumors.
    Bakker GH; Setyono-Han B; Portengen H; De Jong FH; Foekens JA; Klijn JG
    Endocrinology; 1989 Sep; 125(3):1593-8. PubMed ID: 2527151
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-tumour activity of ICI 118630, a new potent luteinizing hormone-releasing hormone agonist.
    Nicholson RI; Maynard PV
    Br J Cancer; 1979 Mar; 39(3):268-73. PubMed ID: 380618
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Effects of chemo-endocrine therapy on DMBA-induced rat mammary carcinoma].
    Yamamoto H; Morimoto T; Monden A
    Nihon Geka Gakkai Zasshi; 1989 Oct; 90(10):1786-92. PubMed ID: 2512479
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Growth inhibition of mouse MXT mammary tumor by the luteinizing hormone-releasing hormone antagonist SB-75.
    Szende B; Srkalovic G; Groot K; Lapis K; Schally AV
    J Natl Cancer Inst; 1990 Mar; 82(6):513-7. PubMed ID: 2156080
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of analogues of luteinizing hormone-releasing hormone for the treatment of cancer.
    Furr BJ; Nicholson RI
    J Reprod Fertil; 1982 Mar; 64(2):529-39. PubMed ID: 6461763
    [No Abstract]   [Full Text] [Related]  

  • 8. [Experimental multihormone therapy on human breast carcinomas grown in nude mice].
    Fukutomi T
    Nihon Geka Gakkai Zasshi; 1989 Dec; 90(12):2021-30. PubMed ID: 2626154
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activity of a new analogue of luteinizing hormone releasing hormone, ICI 118630, on the growth of rat mammary tumours [proceedings].
    Nicholson RI; Finney EJ; Maynard PV
    J Endocrinol; 1978 Nov; 79(2):51P-52P. PubMed ID: 366064
    [No Abstract]   [Full Text] [Related]  

  • 10. [Therapy with LHRH analogs in a 41-year-old patient with metastatic breast cancer].
    Hartmann A; Mann K
    Internist (Berl); 1989 Apr; 30(4):254-7. PubMed ID: 2525538
    [No Abstract]   [Full Text] [Related]  

  • 11. Antiestrogenic and antitumor properties of tamoxifen in laboratory animals.
    Jordan VC
    Cancer Treat Rep; 1976 Oct; 60(10):1409-19. PubMed ID: 828517
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The mode of action of the antitumour agent GP 48,989 in the rat.
    Jordan VC; Dixon B; Prestwich G; Furr BJ
    Eur J Cancer (1965); 1979 May; 15(5):755-61. PubMed ID: 510337
    [No Abstract]   [Full Text] [Related]  

  • 13. Fertility-preserving treatment in young patients with endometrial adenocarcinoma.
    Wang CB; Wang CJ; Huang HJ; Hsueh S; Chou HH; Soong YK; Lai CH
    Cancer; 2002 Apr; 94(8):2192-8. PubMed ID: 12001117
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined tamoxifen and luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist alone in premenopausal advanced breast cancer: a meta-analysis of four randomized trials.
    Klijn JG; Blamey RW; Boccardo F; Tominaga T; Duchateau L; Sylvester R;
    J Clin Oncol; 2001 Jan; 19(2):343-53. PubMed ID: 11208825
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A spontaneous estrogen dependent, tamoxifen sensitive mouse mammary tumor: a new model system to study hormone-responsiveness in immune competent mice.
    Simian M; Manzur T; Rodriguez V; de Kier Joffé EB; Klein S
    Breast Cancer Res Treat; 2009 Jan; 113(1):1-8. PubMed ID: 18183485
    [TBL] [Abstract][Full Text] [Related]  

  • 16. LHRH agonists for adjuvant therapy of early breast cancer in premenopausal women.
    Sharma R; Hamilton A; Beith J
    Cochrane Database Syst Rev; 2008 Oct; (4):CD004562. PubMed ID: 18843661
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An antiangiogenic urokinase-derived peptide combined with tamoxifen decreases tumor growth and metastasis in a syngeneic model of breast cancer.
    Guo Y; Mazar AP; Lebrun JJ; Rabbani SA
    Cancer Res; 2002 Aug; 62(16):4678-84. PubMed ID: 12183425
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Steroid hormone receptors in mammary carcinoma: the effect of tamoxifen.
    Koenders AJ; Beex LV; Geurts-Moespot J; Benraad TJ
    Eur J Cancer (1965); 1980; Suppl 1():63-6. PubMed ID: 7318871
    [No Abstract]   [Full Text] [Related]  

  • 19. Selective estrogen receptor modulators inhibit growth and progression of premalignant lesions in a mouse model of ductal carcinoma in situ.
    Namba R; Young LJ; Maglione JE; McGoldrick ET; Liu S; Wurz GT; DeGregorio MW; Borowsky AD; MacLeod CL; Cardiff RD; Gregg JP
    Breast Cancer Res; 2005; 7(6):R881-9. PubMed ID: 16280035
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Experimental combined hormone therapy on human breast carcinomas serially transplanted into nude mice.
    Fukutomi T; Kubota T; Ikeda T; Isobe Y; Kikuyama S; Shimada A; Nakamura A; Nishiumi T; Enomoto K; Ishibiki K
    Jpn J Cancer Res; 1986 Jan; 77(1):92-7. PubMed ID: 2937762
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.